Prevalence of the Prescription of Potentially Interacting Drugs

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Tragni, Elena ^a   Casula, Manuela ^a   Pieri, Vasco ^a   Favato, Giampiero ^a,b   Marcobelli, Alberico ^c   Trotta, Maria Giovanna ^d   Catapano, Alberico Luigi ^a,e  

^a UNIVERSITY OF MILAN   (Italy)

^b KINGSTON UNIVERSITY   (United Kingdom)

^c Information Flow and Economic Analyses   (Italy)

^d General and Hospital Practice and Drug Policies   (Italy)

^e IRCCS MULTIMEDICA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLARITHROMYCIN; CLOPIDOGREL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GEMFIBROZIL; HEPARIN; INDOMETACIN; ITRACONAZOLE; LEVOTHYROXINE; METFORMIN; METHOTREXATE; MOXIFLOXACIN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; VERAPAMIL; WARFARIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EXPOSURE; DRUG USE; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTION; PRESCRIPTION; PREVALENCE; RETROSPECTIVE STUDY; SEX RATIO;

DRUG INTERACTIONS; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE;

EID: 84885401259     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078827     Document Type: Article

References (51)

1. Astrand B, Astrand E, Antonov K, Petersson G, (2006) Detection of potential drug interactions- a model for a national pharmacy register. Eur J Clin Pharmacol 62: 749-756. doi:10.1007/s00228-006-0143-x. PubMed: 16896788.
2. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA, (2003) Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 289: 1652-1658. doi:10.1001/jama.289.13.1652. PubMed: 12672733.
3. Grymonpre RE, Mitenko PA, Sitar DS, Aoki FY, Montgomery PR, (1988) Drug-associated hospital admissions in older medical patients. J Am Geriatr Soc 36: 1092-1098. PubMed: 3192887.
4. Miranda V, Fede A, Nobuo M, Ayres V, Giglio A, et al. (2011) Adverse drug reactions and drug interactions as causes of hospital admission in oncology. J Pain Symptom Manage 42: 342-353. doi:10.1016/j.jpainsymman.2010.11.014. PubMed: 21454043.
5. McDonnell PJ, Jacobs MR, (2002) Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 36: 1331-1336. doi:10.1345/aph.1A333. PubMed: 12196047.
6. Shad MU, Marsh C, Preskorn SH, (2001) The economic consequences of a drug-drug interaction. J Clin Psychopharmacol 21: 119-120. doi:10.1097/00004714-200102000-00027. PubMed: 11199940.
7. Ernst FR, Grizzle AJ, (2001) Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash) 41: 192-199. PubMed: 11297331.
8. van Roon EN, Flikweert S, Le Comte M, Langendijk PN, Kwee-Zuiderwijk WJ, et al. (2005) Clinical relevance of drug-drug interactions: a structured assessment procedure. Drug Saf 28: 1131-1139. doi:10.2165/00002018-200528120-00007. PubMed: 16329715.
9. Glassman PA, Simon B, Belperio P, Lanto A, (2002) Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care 40: 1161-1171. doi:10.1097/00005650-200212000-00004. PubMed: 12458299.
10. Langdorf MI, Fox JC, Marwah RS, Montague BJ, Hart MM, (2000) Physician versus computer knowledge of potential drug interactions in the emergency department. Acad Emerg Med 7: 1321-1329. doi:10.1111/j.1553-2712.2000.tb00483.x. PubMed: 11073486.
11. Ko Y, Malone DC, Skrepnek GH, Armstrong EP, Murphy JE, et al. (2008) Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers. Drug Saf 31: 525-536. doi:10.2165/00002018-200831060-00007. PubMed: 18484786.
12. Becker ML, Kallewaard M, Caspers PW, Schalekamp T, Stricker BH, (2005) Potential determinants of drug-drug interaction associated dispensing in community pharmacies. Drug Saf 28: 371-378. doi:10.2165/00002018-200528050-00001. PubMed: 15853439.
13. Malone DC, Abarca J, Skrepnek GH, Murphy JE, Armstrong EP, et al. (2007) Pharmacist workload and pharmacy characteristics associated with the dispensing of potentially clinically important drug-drug interactions. Med Care 45: 456-462. doi:10.1097/01.mlr.0000257839.83765.07. PubMed: 17446832.
14. Malone DC, Hutchins DS, Haupert H, Hansten P, Duncan B, et al. (2005) Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm 62: 1983-1991. doi:10.2146/ajhp040567. PubMed: 16174833.
15. Zhan C, Correa-de-Araujo R, Bierman AS, Sangl J, Miller MR, et al. (2005) Suboptimal prescribing in elderly outpatients: potentially harmful drug-drug and drug-disease combinations. J Am Geriatr Soc 53: 262-267. doi:10.1111/j.1532-5415.2005.53112.x. PubMed: 15673350.
16. Favato G, Mariani P, Mills RW, Capone A, Pelagatti M, et al. (2007) ASSET (Age/Sex Standardised Estimates of Treatment): a research model to improve the governance of prescribing funds in Italy. PLOS ONE 2: e592. doi:10.1371/journal.pone.0000592. PubMed: 17611624.
17. (2008) AIFA. Linee guida per la classificazione e conduzione degli studi osservazionali sui farmaci. GU n. 76. Italy: AIFA.
18. World Health Organization W ATC/DDD Index 2009.
19. AIFA (2005) Rapporto OSMED 2004. Roma: Ministero della Salute.
20. Tobi H, Faber A, van den Berg PB, Drane JW, de Jong-van den Berg LT, (2007) Studying co-medication patterns: the impact of definitions. Pharmacoepidemiol Drug Saf 16: 405-411. doi:10.1002/pds.1304. PubMed: 16981229.
21. Gagne JJ, Maio V, Rabinowitz C, (2008) Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy. J Clin Pharm Ther 33: 141-151. doi:10.1111/j.1365-2710.2007.00891.x. PubMed: 18315779.
22. Bjerrum L, Lopez-Valcarcel Gonzalez. B, Petersen G (2008) Risk factors for potential drug interactions in general practice. Eur J Gen Pract 14: 23-29.
23. Smith DR, L'Abbate N, Lorusso A, (2008) Tobacco smoking among Italian physicians and the role of occupational medicine. Med Lav 99: 3-7. PubMed: 18254534.
24. Bjerrum L, Andersen M, Petersen G, Kragstrup J, (2003) Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 21: 153-158. doi:10.1080/02813430310001806. PubMed: 14531506.
25. Guédon-Moreau L, Ducrocq D, Duc MF, Quieureux Y, L'Hôte C, et al. (2004) Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999. Eur J Clin Pharmacol 59: 899-904. doi:10.1007/s00228-003-0709-9. PubMed: 14685802.
26. Chen YF, Avery AJ, Neil KE, Johnson C, Dewey ME, et al. (2005) Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf 28: 67-80. doi:10.2165/00002018-200528010-00005. PubMed: 15649106.
27. Magro L, Conforti A, Del Zotti F, Leone R, Iorio ML, et al. (2008) Identification of severe potential drug-drug interactions using an Italian general-practitioner database. Eur J Clin Pharmacol 64: 303-309. doi:10.1007/s00228-007-0394-1. PubMed: 17992523.
28. Malone DC, Abarca J, Hansten PD, Grizzle AJ, Armstrong EP, et al. (2004) Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. J Am Pharm Assoc (2003) 44: 142-151.
29. Peng CC, Glassman PA, Marks IR, Fowler C, Castiglione B, et al. (2003) Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population. J Manag Care Pharm 9: 513-522. PubMed: 14664659.
30. Zwart-van Rijkom JE, Uijtendaal EV, ten Berg MJ, van Solinge WW, Egberts AC, (2009) Frequency and nature of drug-drug interactions in a Dutch university hospital. Br J Clin Pharmacol 68: 187-193. doi:10.1111/j.1365-2125.2009.03443.x. PubMed: 19694737.
31. Hatton RC, Rosenberg AF, Morris CT, McKelvey RP, Lewis JR,. (2011) Evaluation of contraindicated drug-drug interaction alerts in a hospital setting. Ann Pharmacother 45: 297-308. doi:10.1345/aph.1P533. PubMed: 21386026.
32. Oertle M,. (2012) Frequency and nature of drug-drug interactions in a Swiss primary and secondary acute care hospital. Swiss Med Wkly 142: 0. PubMed: 23188555.
33. Hohl CM, Dankoff J, Colacone A, Afilalo M, (2001) Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med 38: 666-671. doi:10.1067/mem.2001.119456. PubMed: 11719747.
34. Puckett WH Jr., Visconti JA, (1971) An epidemiological study of the clinical significance of drug-drug interactions in a private community hospital. Am J Hosp Pharm 28: 247-253. PubMed: 5094043.
35. Jonville-Béra AP, Béra F, Autret-Leca E, (2005) Are incorrectly used drugs more frequently involved in adverse drug reactions? A prospective study. Eur J Clin Pharmacol 61: 231-236. doi:10.1007/s00228-004-0881-6. PubMed: 15824914.
36. Jankel CA, Fitterman LK, (1993) Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 9: 51-59. doi:10.2165/00002018-199309010-00005. PubMed: 8347291.
37. Jankel CA, Speedie SM, (1990) Detecting drug interactions: a review of the literature. DICP 24: 982-989. PubMed: 2244413.
38. Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, et al. (2007) Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf 16: 641-651. doi:10.1002/pds.1351. PubMed: 17154346.
39. Warholak TL, Hines LE, Song MC, Gessay A, Menke JM, et al. (2011) Medical, nursing, and pharmacy students' ability to recognize potential drug-drug interactions: a comparison of healthcare professional students. J Am Acad Nurse Pract 23: 216-221. doi:10.1111/j.1745-7599.2011.00599.x. PubMed: 21489016.
40. Sorensen TD, Traynor AP, Janke KK, (2009) A pharmacy course on leadership and leading change. Am J Pharm Educ 73: 23. doi:10.5688/aj730223. PubMed: 19513161.
41. AIFA (2006) Rapporto OSMED 2005. Roma: Ministero della Salute.
42. Oates JA, (1988) Antagonism of antihypertensive drug therapy by nonsteroidal anti-inflammatory drugs. Hypertension 11: II4-II6. doi:10.1161/01.HYP.11.3_Pt_2.II4. PubMed: 3280491.
43. Pavlicević I, Kuzmanić M, Rumboldt M, Rumboldt Z, (2008) Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol 15: e372-e382. PubMed: 18953082.
44. Hersh EV, Pinto A, Moore PA, (2007) Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clin Ther 29 (Suppl):: 2477-2497. doi:10.1016/j.clinthera.2007.12.003. PubMed: 18164916.
45. Mehlhorn AJ, Brown DA, (2007) Safety concerns with fluoroquinolones. Ann Pharmacother 41: 1859-1866. doi:10.1345/aph.1K347. PubMed: 17911203.
46. Weideman RA, Bernstein IH, McKinney WP, (1999) Pharmacist recognition of potential drug interactions. Am J Health Syst Pharm 56: 1524-1529. PubMed: 10478990.
47. Cavuto NJ, Woosley RL, Sale M, (1996) Pharmacies and prevention of potentially fatal drug interactions. JAMA 275: 1086-1087. doi:10.1001/jama.1996.03530380028022. PubMed: 8601923.
48. Karas S Jr., (1981) The potential for drug interactions. Ann Emerg Med 10: 627-630. doi:10.1016/S0196-0644(81)80085-6. PubMed: 7305093.
49. Shah NR, Seger AC, Seger DL, Fiskio JM, Kuperman GJ, et al. (2006) Improving acceptance of computerized prescribing alerts in ambulatory care. J Am Med Inform Assoc 13: 5-11. doi:10.1197/jamia.M1868. PubMed: 16221941.
50. Weingart SN, Simchowitz B, Shiman L, Brouillard D, Cyrulik A, et al. (2009) Clinicians' assessments of electronic medication safety alerts in ambulatory care. Arch Intern Med 169: 1627-1632. doi:10.1001/archinternmed.2009.300. PubMed: 19786683.
51. Cruciol-Souza JM, Thomson JC, (2006) Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci 9: 427-433. PubMed: 17207423.